On 20 August 2020, three prominent religious leaders in Australia wrote to the Prime Minister to express concerns about the ethical dilemma associated with calls to make vaccination for COVID-19 mandatory.
This followed the announcement that the Australian Government had signed a letter of intent to secure supply of the AstraZeneca/Oxford University COVID-19 vaccine should the current clinical trials prove successful.
The central concern is that the production of the vaccine uses a cell line HEK-293 that is cultured from electively aborted human foetus and that the Australian Government should support supply of an alternative uncontroversial vaccine if mandatory vaccination for COVID-19 is to be introduced.
Read more
Given the implications for potential take-up of a vaccine, its important to unpack this concern as well as the general ethical concerns from using human cell lines.
Manufacturing of the Oxford vaccine involves human kidney cells. These cells are used as factories to make the component of the vaccine that carries genes from the SARS-CoV-2 virus with the aim of triggering an immune response to protect the recipient when injected.
The type of cells used are descendants of cells first obtained in the early 1970s, from a foetus which was probably electively aborted (although records have now been lost).
These cells were cultured in the laboratory to produce what is called a cell line, a population of cells that have adapted to grow continuously in culture while retaining uniform characteristics.
Once created, cell lines are usually shared with researchers in different laboratories and referred to by a simple reference code. In the case of this foetal cell line it was called HEK-293.
Read more
Even though the descendants of foetal cells are used to produce the vaccine, the actual vaccination does not contain any foetal cells, or pieces of foetal DNA.
This cell line, and others like it, are commonly used in medical research. Indeed six of the COVID-19 vaccine candidates in development across the globe use human foetal cell lines.
Foetal cells derived from elective terminations of pregnancy have been commonly used in scientific research since the 1960s.
Their unique properties, such as an ability to be grown easily in the lab into cell lines, and the extensive knowledge about these cells gathered over decades of research, has seen them used to manufacture many vaccines, including those commonly used against rubella, chickenpox, hepatitis A, and shingles.
Again like in the production of the Oxford vaccine, there is no residual foetal cells or DNA in the actual vaccines.
Foetal cells have also been used to make approved drugs against diseases including haemophilia, rheumatoid arthritis, and cystic fibrosis and to study infectious diseases like Zika and HIV.
Read more
It is important to clarify that while foetal cells are sometimes referred to as embryonic cell lines, this should not be confused with the use of human embryos or creation of embryonic stem cells.
Foetal cells are obtained from donated tissue following termination of pregnancy or spontaneous miscarriage, while embryonic stem cells are obtained from donated human embryos originally created in the course of infertility treatment at an IVF clinic.
The term embryonic can refer to a stage of development both before and after a pregnancy is established.
HEK-293 cell line may be correctly described as being from embryonic kidney cells but is quite different to the use of human embryos to make an embryonic stem cell line that could be used in research to understand kidney disease or how kidneys develop.
The use of human embryos in research is highly regulated in Australia and elsewhere across the globe. While advances in stem cell research have reduced the need for foetal cells in certain areas of research, there remains a clear need for foetal tissue research.
The letter to the Prime Minister cites concerns that using products from the HEK-293 line amounts to benefiting from an elective termination, and therefore makes one complicit in a moral wrong.
Read more
This is only a concern for people who believe terminating a pregnancy is a moral wrong. This position would have far-ranging implications for public health, beyond the use of the Oxford vaccine.
Many currently available vaccines, and some other COVID-19 vaccine candidates, are produced using foetal cell lines.
More fundamentally the use of foetal cells lines is a ubiquitous part of medical research, leading to many techniques and drugs that are commonly used in medicine and have contributed to advances that have saved many lives.
Even those who have no moral objection to elective termination of pregnancy may have other concerns about the use of human or animal cell lines.
Ethical standards have improved greatly in the last few decades, and we need to confront some ethically suspect practices of the past. But one way we should respond to past bad practices is to learn from them and improve our standards.
In Australia, research using foetal tissue is subject to careful oversight under the National Statement on Ethical Conduct in Human Research (National Statement), which exemplifies the values of respect, research merit and integrity, justice, and beneficence.
Read more
The National Statement acknowledges that human research carries a potential risk of harm, discomfort and/or inconvenience for participants and/or others and therefore requires that the potential benefits of the research justify any risks involved.
It also requires that those who conscientiously object to being involved in conducting research with foetal tissue are not compelled to participate or put at a disadvantage because of their objection. This concession reflects the value of respect for human life and the beliefs of those involved in research.
While one of the letters authors, Sydneys Archbishop Anthony Fisher, has subsequently stressed that he does not think that it would be unethical to use this vaccine if there is no alternative available, and that he wont be critical of anyone who uses the vaccine.
His call for ethically untainted alternative might be difficult to meet given the long and deep role that foetal tissue has played in medical research.
Its unlikely that any COVID-19 vaccine will be entirely free from the use foetal cell lines, as some knowledge gained from those cell lines will go into any vaccine that is created.
Read more
While this issue may not be easily resolved, it is important to continue discussing ethical issues as we race to develop safe and effective treatments and/or vaccines for COVID-19.
As acknowledged in the National Statement, the risks and benefits of human research must always be considered to promote ethically good research.
The development of a safe and effective vaccine for COVID-19 carries significant benefit for the community, thereby promoting the values of research merit and integrity and beneficence.
Another core value in the National Statement is justice, which includes procedural justice (fair treatment in the recruitment of participants and the review of research) and distributive justice (fair distribution of the benefits and burdens of research).
As new vaccines are developed, it will therefore be important to uphold rigorous ethical standards in both laboratory and clinical research and ensure equitable distribution of the vaccine on a global scale.
Banner: Getty Images
Read the original:
Gaining clarity on the ethical issues of a possible COVID-19 vaccine - Pursuit
- Experimental cell therapy trial treats first Sjgrens disease patient - University of Wisconsin School of Medicine and Public Health - February 11th, 2025
- Stem Cell Therapy Market Types, Applications, Share, Growth - openPR - February 6th, 2025
- Placental Stem Cell Therapy Solution Market Size And Booming - openPR - February 6th, 2025
- Revitalizing Health with Stem Cell Therapy: A Groundbreaking Path To Longevity and Wellness - openPR - February 4th, 2025
- Gene therapy offers new hope for sickle cell disease patients - Open Access Government - February 4th, 2025
- Scientists trial implant to patch up the heart - BBC.com - February 2nd, 2025
- Cell Therapy Market Size is Projected to Reach USD 33.93 - GlobeNewswire - January 28th, 2025
- Meet the California Institute Pushing Stem Cell & Gene Therapy Research: Part 3 - The Medicine Maker - January 28th, 2025
- Immusoft to Present Positive Data from the First Engineered B Cell in a Human Clinical Trial at the 21st Annual WorldSymposium 2025 - The Eastern... - January 28th, 2025
- Beyond the Lab: Stem cell research - Drug Target Review - January 25th, 2025
- Asia Pacific Stem Cell Therapy Market to Reach US$ 4,075.75 Million by 2033 with a Robust CAGR of 10.29% - openPR - January 25th, 2025
- Exciting data: S.Biomedics preps US IND of PD cell therapy - BioWorld Online - January 25th, 2025
- $24.85 Billion Cell Therapy Market Forecast by 2032 (CAGR 20.4%) - openPR - January 25th, 2025
- Stem Cell Therapy Market Expected to Expand at a Steady 2025-2032 - openPR - January 25th, 2025
- Regenerative Medicine Market to receive overwhelming hike US$ 164.9 billion in Revenues by 2032, Growing at a CAGR of 23.30% From 2024 to 2032 -... - January 25th, 2025
- Alternative medicine fans see RFK Jr. as a hero. The fields skeptics worry. - The Washington Post - January 23rd, 2025
- U.S. PRP and Stem Cell Alopecia Treatment Market Analysis 2025-2030 by Treatment, Indication, and End-use - Androgenic Alopecia Dominated the Market... - January 23rd, 2025
- The Future of Regenerative Medicine Lies in the Hands of Chiropractors - Dynamic Chiropractic - January 23rd, 2025
- Stem Cell Therapy Industry Dynamics and Contributions by RTI - openPR - January 21st, 2025
- Stem Cells Market to Reach USD 44.27 Billion by 2033, Driven by Expanding Applications and Innovations - openPR - January 21st, 2025
- Organoids at the Forefront Innovations in Stem Cell Research and Precision Medicine - openPR - January 21st, 2025
- The promising future of regenerative medicine - Yahoo Finance - January 17th, 2025
- An earful of gill: USC Stem Cell study points to the evolutionary origin of the mammalian outer ear - EurekAlert - January 11th, 2025
- Aspen Partners with Mytos to Automate Stem Cell Production for Parkinsons Therapy - Genetic Engineering & Biotechnology News - January 9th, 2025
- School of Medicine professor receives grant to study improved cancer treatments - Mercer University - January 9th, 2025
- Meet CIRM: the California Institute Pushing Stem Cell and Gene Therapy Research: Part 1 - The Medicine Maker - January 7th, 2025
- Regenerative Medicine Market to Experience Significant Growth, Projected to Reach $183.08 Billion by 2031. - openPR - January 7th, 2025
- Stem-cell therapies that work: 10 Breakthrough Technologies 2025 - MIT Technology Review - January 5th, 2025
- 1st stem cell therapy, new HIV drug approved - ecns - January 5th, 2025
- Science fiction turned reality? Stem cell therapy set to repair child's heart - Ynetnews - January 3rd, 2025
- Stem Health Plus Revolutionizes Skin Regeneration with Advanced Stem Cell Skin Graft Technology - The Manila Times - January 1st, 2025
- Allogeneic Stem Cell Transplantation Market Size to Expand Lucratively by 2031 - openPR - January 1st, 2025
- Apoptotic clearance by stem cells: molecular mechanisms for recognition and phagocytosis of dead cells - Nature.com - December 30th, 2024
- Why Medical Tourists are Choosing Mexico: The Affordable Alternative for Advanced Stem Cell Treatments - openPR - December 30th, 2024
- Induced Pluripotent Stem Cells (iPSC) Production Market: Trends, Growth, and the Role of AI - openPR - December 30th, 2024
- Stem cells 'instructed' to form specific tissues and organs - New Atlas - December 28th, 2024
- Stem Cell Transplantation Still the Main Treatment Option for Beta-Thalassemia - Medpage Today - December 28th, 2024
- Black Group Investment Partners with Zenzic Oasis to Advance Stem Cell Therapy for Personalised Medicine - Galveston County Daily News - December 28th, 2024
- Black Group Investment Partners with Zenzic Oasis to Advance Stem Cell Therapy for Personalised Medicine - Voice Of Alexandria - December 28th, 2024
- U.S. Stem Cell Therapy Market Revenue to Attain USD 17.70 Bn by 2033 - Precedence Research - December 27th, 2024
- Here are some biggest medical breakthroughs of 2024 - Medical Buyer - December 27th, 2024
- Researchers from Korea University explore how ascorbic acid and FGF4 revolutionize regenerative medicine - EurekAlert - December 27th, 2024
- Regenerative Medicine Market to Skyrocket to USD 73,084.2 Million by 2033 at a 18.5% of CAGR - openPR - December 27th, 2024
- Stem cell therapy to correct heart failure in children could 'transform lives' - Fox News - December 25th, 2024
- Advancing type 1 diabetes therapy: autologous islet transplant breakthrough - Nature.com - December 25th, 2024
- Stem Cell Therapy Market to Triple in Value, Reaching USD 52.1 Billion by 2034 at a 12.1% of CAGR - openPR - December 25th, 2024
- Stem-cell therapies: A breakthrough in treating parkinson's, cancer, diabetes, and more - The Business Standard - December 25th, 2024
- Replay 2024 : 6 Biggest Medical Breakthroughs Of 2024 - NewsX - December 25th, 2024
- Tumbling stem cells? Watch how movement plays a part in their fate - Scope - December 20th, 2024
- SCD patients free of VOEs after treatment with gene-editing therapy - Sickle Cell Disease News - December 20th, 2024
- Japan's Sumitomo to establish regenerative medicine and cell therapy joint venture - BSA bureau - December 20th, 2024
- Brain cells remain healthy after a month on the International Space Station, but mature faster than brain cells on Earth - EurekAlert - December 19th, 2024
- Reindeers Pave the Way for Regenerative Medicine - The Scientist - December 19th, 2024
- Johnson & Johnson submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA (ibrutinib) in adult... - December 19th, 2024
- What Role Does Regenerative Medicine Play In The Management Of Type 1 And Type 2 Diabetes? - TheHealthSite - December 19th, 2024
- World's 1st Stem Cell Book on Animals, Reveals How to Extend the Lives of Pets - PR Newswire - December 17th, 2024
- Accelerated Biosciences and Stemmatters Collaborate to Offer iPSC Derived from Human Trophoblast Stem Cells - Business Wire - December 17th, 2024
- Stem Cells: Hope on the Horizon for Preterm Babies - Monash University - December 17th, 2024
- Stem Cell Transplant Offers No Difference in OS or PFS in Mantle Cell Lymphoma Compared with Maintenance Therapy Alone - OncoZine - December 17th, 2024
- Inside One Mans Journey with Multiple Myeloma - Men's Health - December 15th, 2024
- Stem Cells Market Size to Reach USD 48.83 Billion By 2034 - Exclusive Report by Precedence Research - BioSpace - December 13th, 2024
- Treating Heart Defects with Tissue-engineered Vascular Conduits - Yale School of Medicine - December 13th, 2024
- Tom Curry: England flanker has stem-cell therapy in bid to make 2027 World Cup - BBC.com - December 13th, 2024
- Stem Cell Manufacturing Market Dynamics Key Drivers Challenges and Technological Innovations - Set to reach USD 26.6 billion by 2033 - PharmiWeb.com - December 13th, 2024
- Stem Cell Therapy Market Is Expected To Reach Revenue Of USD 54.7 Bn By 2033, At 12.6% CAGR: Dimension Market Research - The Manila Times - December 13th, 2024
- Stem cell transplantation could save the coral reefs - Ynetnews - December 13th, 2024
- Vitrification Market | Driving Innovations in Cryopreservation for Fertility Treatments and Regenerative - EIN News - December 13th, 2024
- Workshop on Regenerative Medicine concludes at SKUAST-K - Greater Kashmir - December 13th, 2024
- High-dose chemotherapy followed by autologous stem cell transplant ineffective for patients with mantle cell lymphoma - News-Medical.Net - December 11th, 2024
- Stem Cell Therapy Market Is Expected To Reach Revenue Of - GlobeNewswire - December 11th, 2024
- Stem Cell Therapy Market to Worth Over US$ 2,612.92 Million By 2033 | Astute Analytica - GlobeNewswire - December 11th, 2024
- Changes in Blood Cell Production Over the Lifetime | Newswise - Newswise - December 7th, 2024
- Study reveals how stem cells respond to environmental signals, with implications for IBD and colorectal cancer - Medical Xpress - December 5th, 2024
- Stem cell therapy TED-A9 showing safety and early efficacy in trial - Parkinson's News Today - December 5th, 2024
- BMP-2 loaded scaffold for stem and immune cell recruitment in therapeutic applications - News-Medical.Net - December 5th, 2024
- Stem Cell Treatment May Help To Cure Vision Loss - Anti Aging News - December 5th, 2024
- BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024... - December 3rd, 2024
- Stem Cell Therapy Strategic Business Report 2024 - - GlobeNewswire - December 3rd, 2024
- Enhancing the efficacy of cell transplantation therapy for stroke or traumatic brain injury - Medical Xpress - December 1st, 2024
- Apheresis in Cellular Therapies: Unlocking Quality for CAR T and Stem Cell Treatments, Upcoming Webinar Hosted by Xtalks - PR Web - November 29th, 2024
Recent Comments